Please activate JavaScript!
Please install Adobe Flash Player, click here for download

EH 1_2016

Editor-in-Chief: Brenda Marsh Art Director: Olaf Skrober Managing Editor: Sylvia Schulz Editorial team: Sascha Keutel, Marcel Rasch Senior Writer: John Brosky Executive Director: Daniela Zimmermann Founded by Heinz-Jürgen Witzke Correspondents Austria: Michael Kraßnitzer, Christian Pruszinsky. China: Nat Whitney France: Annick Chapoy, Jane MacDougall. Germany: Anja Behringer, Annette Bus, Walter Depner, Bettina Döbereiner, Matthias Simon, Axel Viola, Cornelia Wels-Maug, Holger Zorn. Great Britain: Brenda Marsh, Mark Nicholls. Malta: Moira Mizzi. Poland: Pjotr Szoblik. Russia: Olga Ostrovskaya, Alla Astachova. Spain: Mélisande Rouger, Eduardo de la Sota. Switzerland: Dr. André Weissen. USA: Cynthia E. Keen, i.t. Communications, Nat Whitney. Subscriptions Janka Hoppe, European Hospital, Theodor-Althoff-Str. 45, 45133 Essen, Germany Subscription rate 6 issues: 42 Euro, Single copy: 7 Euro. Send order and cheque to: European Hospital Subscription Dept Printed by: WVD, Mörfelden-Walldorf, Germany Publication frequency: bi-monthly European Hospital ISSN 0942-9085 Representatives China & Hongkong: Gavin Hua, Sun China Media Co, Ltd. Phone: +86-0755-81 324 036 E-Mail: gh@european-hospital.com Germany, Austria, Switzerland: Ralf Mateblowski Phone: +49 6735 912 993, E-Mail: rm@european-hospital.com France, Italy, Spain: Eric Jund Phone: +33 493 58 77 43, E-Mail: ej@european-hospital.com GB, Scandinavia, BeNeLux: Simon Kramer Phone/Fax: +31 180 6200 20 E-Mail: sk@european-hospital.com Israel: Hannah Wizer, International Media Dep. of El-Ron Adv. & PR Co., Ltd., Phone: +972-3-6 955 367 E-Mail: hw@european-hospital.com South Korea: CH Park, MCI Phone: +82 2 730 1234, E-Mail: chp@european-hospital.com USA & Canada: Hanna Politis, Media International Tel: +1 301 869 66 10, E-Mail: hp@european-hospital.com www.healthcare-in-europe.com 27 EH @ ECR A bright outlook for bona fide personalised medicine Big data in cardiac CT Report: Michael Krassnitzer CT angiography (CTA) is evolving from a morphological – anatomical – to a functional imaging modality. In the past two years, cardiac CT perfusion measurement techniques were launched that predict which lesion will cause a reduction in blood flow. ‘We are get- ting closer to our objective: to be able to predict, by non-invasive means, the consequences of a stenosis in a individu- al coronary heart disease patient and to evaluate wheth- er and which intervention will be useful,’ says Uwe Joseph Schöpf MD, professor of radiology, cardiol- ogy and paediatrics and Director of Cardiovascular Imaging at the Medical University of South Carolina in Charleston, SC, adding: ‘This is bona fide personalised medicine.’ Today, tube voltage and tube current are automatically adapted to each individual patient during a cardiac CT scan. Moreover, the new generation of multi-detector CT systems offer new insights: dual energy scanners, i.e. scanners that use two tubes in one scan, enable assessment of blood content in the heart muscle. ‘We can directly and dynamically measure blood flow within the heart by scanning quick- ly back and forth across it while the contrast agent bolus moves through the heart muscle,’ Professor Schöpf explains. Another promising technology is the single photon detector, cur- rently under development. ‘These detectors allow us to look at each individual photon and its behaviour which pro- vides new data for tissue characterisation, for example the distri- bution of iodine in the body,’ he adds. The development of new algorithms and statistical proce- dures is contributing to the rapid progress in imaging technologies. Thermodynamic models are being used to predict blood flow, or even more impressive, artificial intelli- gence concepts are applied in radi- ology. Computers ‘learn’ by analys- ing hundreds of cases of coronary stenoses to determine which steno- sis will be dangerous for the patient. Schöpf sees enormous potential: ‘This is a Big Data application, but by no means science fiction. Initial results are expected to be published later this year.’ The new techniques and pro- cedures have an important posi- tive side effect: radiation dose will be drastically reduced again. Today, a full CTA can be performed at 80 kV with 30 ml con- trast. A study at the Medical University of South Carolina, co-authored by Professor Schöpf (Spearman et al, Radiology, 16 Oct 2015) indicates that the intro- duction of auto- mated kV selec- tion in 80,000 exams, world- wide, reduced average radiation dose by 14 percent – a result which, a few years ago would have been considered revolutionary. Albeit, as Professor Schöpf points out, ‘Here, in the US, the discussion about radiation dose is petering out. Radiation dose as a dominant issue, above all in the USA, appears to have been largely a matter of domestic political interests. Many radiologists assume that radia- tion dose was used to prepare the ground for ‘ObamaCare’: an argu- ment to decrease the use of imaging in order to save as much money as possible in the context of the planned US healthcare reform.’ Today, with President Barack Obama’s healthcare reform being well established ‘the issue of radia- tion dose has all but disappeared,’ Schöpf observed. However, on the level of technol- ogy dose reduction remains impor- tant, the professor emphasises. The objective is to further reduce radiation and contrast dose while achieving the same high level of image quality. According to Schöpf, results so far are encouraging and, in some cases, image quality was even enhanced. ‘What we need to do now,’ he believes, ‘is to enhance our diagnostic expertise.’ Tissue characterisation, dual ener- gy, single photon detectors – these are the current top priorities on the research agenda. However, for Schöpf there are even more important questions to be answered: ‘We know that CTA is a good, precise and patient-friendly procedure. Now we need to ask how we can make best possible use of this procedure. Is it cost-efficient? Which clinical scenarios can we envisage? Which patient cohorts will benefit most from these new proce- dures? Where should these exams be performed? These are crucial issues we must deal with in the coming years.’ While clinical evi- dence does exist, as Schöpf points out, ‘Our focus is on the creation of even more evidence that tells us where CTA should be applied.’ Austrian-born Uwe Joseph (Joe) Schöpf is a professor with appointments in Radiology, Cardiovascular Medicine and Paediatrics at the Medical University of South Carolina (MUSC) in Charleston, SC. There he directs the Cardiovascular Imaging Division and is Director of Computed Tomography Research and a Director of the University Designated Centre for Biomedical Imaging. Schöpf grew up in Munich, Germany, where he graduated in medicine at Ludwig Maximilian University (LMU) and received specialist training at its Institute of Clinical Radiology. In 2001, already an accomplished radiologist, he left Munich to pursue his interest in cardiothoracic imaging at Brigham and Women’s Hospital, Harvard Medical School, in Boston, MA. The professor joined MUSC in 2004. Difficult to diagnose: lesion-specific ischemia Cardiac CT (FFR-CT) enables the determination of the fractional flow reserve (FFR) in the coronary arteries during CTA Phone: +86-0755-81324036 Phone: +496735912993, E-Mail: rm@european-hospital.com Phone: +33493587743, E-Mail: ej@european-hospital.com Phone/Fax: +31180620020 & PR Co., Ltd., Phone: +972-3-6955367 Phone: +8227301234, E-Mail: chp@european-hospital.com Tel: +13018696610, E-Mail: hp@european-hospital.com

Pages Overview